Evidence map›Paper›PMID 31165085›Full record

ArticleTransplantation direct2019

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients.

Matthew G Cehic, Christopher A Muir, Jerry R Greenfield, Christopher Hayward, Andrew Jabbour, Anne Keogh, Eugene Kotlyar, Kavitha Muthiah, Peter S Macdonald

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Transplant Recipients: A Systematic Review and Meta-analyses.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Pooled it
  2. Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients with Diabetes Mellitus Following Heart Transplantation: A Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Empagliflozin Use in Cardiac Transplant Patients:Sultan Qaboos University medical journal · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Matthew G CehicFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Christopher A MuirDepartment of Diabetes and Endocrinology, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Jerry R GreenfieldFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Christopher HaywardFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Andrew JabbourFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Anne KeoghFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Eugene KotlyarFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Kavitha MuthiahFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Peter S MacdonaldFaculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Victor Chang Cardiac Research Institute · AUUNSW Sydney · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) is prevalent in patients undergoing heart transplant, and in those without preexisting T2DM, posttransplant diabetes mellitus may develop. Both T2DM and posttransplant diabetes mellitus have been associated with increased morbidity and mortality following heart transplantation. Empagliflozin is an effective glucose-lowering therapy that reduces the incidence of major cardiovascular events in patients with T2DM. The safety and efficacy of empagliflozin in transplant patients with diabetes mellitus has yet to be established.

methodsClinical outcomes were retrospectively examined in 22 heart transplant recipients treated with empagliflozin and compared with those of 79 heart transplant patients with diabetes mellitus receiving alternative glucose-lowering therapies.

resultsThree adverse events were recorded in empagliflozin-treated patients, leading to treatment discontinuation in 1. There were no genitourinary infections. Treatment with empagliflozin for 12 months was associated with reductions in weight, body mass index, glycated hemoglobin, and frusemide dose that were not seen in the control group. There were no large changes observed in blood pressure (systolic or diastolic) or renal function (serum urea, creatinine, or estimated glomerular filtration rate) after 12 months of treatment with empagliflozin or alternative glucose-lowering therapies.

conclusionsEmpagliflozin appears safe and effective in the management of selected patients with diabetes mellitus following heart transplantation.

Identifiers

PMID31165085
PMCPMC6511439
OpenAlexW2940695156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.